126 related articles for article (PubMed ID: 1611621)
1. Induction of antitumor activities in spleen cells from mice and rats activated with lipopolysaccharide immobilized on beads.
Abe H; Tani T; Shibata J; Kodama M
Cancer Immunol Immunother; 1992; 35(1):39-45. PubMed ID: 1611621
[TBL] [Abstract][Full Text] [Related]
2. [Antitumor effect of LPS immobilized beads].
Abe H
Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):627-35. PubMed ID: 1886567
[TBL] [Abstract][Full Text] [Related]
3. On-line cell manipulation for cancer treatment.
Tani T; Numa K; Abe H; Yokota T; Kodama M
Artif Organs; 1992 Jun; 16(3):243-7. PubMed ID: 10078253
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.
Kuroki Y; Ochiai H; Kurokawa M; Niwayama S; Kishimoto C; Tazawa K; Fujimaki M
J Cancer Res Clin Oncol; 1991; 117(2):109-14. PubMed ID: 2007609
[TBL] [Abstract][Full Text] [Related]
5. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
6. [Induction of lymphokine activated killer (LAK) and prolongation of its activity by intrasplenic injection of interleukin 2 (IL-2) in combination with tumor necrosis factor (TNF)].
Nakajima I; Okuno K; Ohnishi H; Shilayama Y; Nakamura T; Hirohata T; Yasutomi M
Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1548-53. PubMed ID: 2263237
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
8. [In vivo antitumor effect of LAK cells induced from various lymphocytes--experimental study in rats].
Goshima H; Saji S; Tanemura H; Takao H; Tachibana S; Oiwa T; Keshikawa I
Nihon Geka Gakkai Zasshi; 1989 Jul; 90(7):972-9. PubMed ID: 2796984
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
Rodolfo M; Salvi C; Bassi C; Parmiani G
Cancer Immunol Immunother; 1990; 31(1):28-36. PubMed ID: 2306753
[TBL] [Abstract][Full Text] [Related]
11. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.
Felgar RE; Hiserodt JC
Cell Immunol; 1990 Sep; 129(2):288-98. PubMed ID: 2383892
[TBL] [Abstract][Full Text] [Related]
12. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
Tjota A; Zhang YQ; Piedmonte MR; Lee CL
J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
15. Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity.
Kawase I; Komuta K; Shirasaka T; Hara H; Tanio Y; Watanabe M; Saito S; Ikeda T; Masuno T; Kishimoto S
Jpn J Cancer Res; 1989 Nov; 80(11):1089-97. PubMed ID: 2514171
[TBL] [Abstract][Full Text] [Related]
16. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
18. Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.
Zanovello P; Rosato A; Bronte V; Mandruzzato S; Cerundolo V; Collavo D
Cancer Immunol Immunother; 1992; 35(1):27-32. PubMed ID: 1611620
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide exposure inhibits induction of lymphokine-activated killer cells by inducing precursor apoptosis.
Samlowski WE; Yim CY; McGregor JR
Nitric Oxide; 1998; 2(1):45-56. PubMed ID: 9706742
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
